Coronary artery stents: a rapid systematic review and economic evaluation

Abstract

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS, the public...

The cost-effectiveness of drug-eluting stents: a systematic review

“…Compared with the earlier studies, later studies by health technology assessment agencies were in general more extensive, were of higher quality, had no industry sponsorship and argued that widespread use of drug-eluting stents was economically unattractive and that a more focused approach concentrating on high-risk patients was indicated. 21,23,24,33,34 Because of their later publication date, their appearance in nonclinical journals and their length and complexity, their impact on clinicians' practices may be lower than that of earlier, more enthusiastic articles published in clinical journals. In 2006, there appears to have been a rebuttal with 3 additional articles favouring widespread use.…”

“…[references 18,20,21,23,24,[26][27][28]33] Included n = 1 subjectivity. Scores on the QHES scale vary from 0 to 100, with higher scores indicating better quality.…”

Drug-eluting stents: a systematic review and economic evaluation

“…Although effective for treating coronary artery stenosis, many (20-50%) patients develop restenosis within 6 months of treatment, requiring further intervention. 2 The reasons for this have been explained through three mechanisms: elastic recoil of the vessel wall, remodelling of the vessel and proliferation of the innermost layer of the vessel wall (neointimal proliferation -growth of cellular matrix in and around a stent and a reaction to tissue injury).…”

“…2 NICE subsequently issued guidance and, as the use of DES was seen to be a rapidly evolving technology, an early date was set to review the guidance. 3 …”

Long‐Term Clinical Outcomes After Angiographically Defined Very Late Stent Thrombosis of Drug‐Eluting Stent

“…1,2 The advent of DES has also raised safety concerns regarding stent thrombosis (ST), which is a catastrophic, albeit infrequent, complication that results in myocardial infarction (MI) or sudden cardiac death. 3,4 However, little is known about the long-term clinical outcomes after very late stent thrombosis (VLST) detection and this study is aimed at assessing longterm clinical outcomes after angiographically documented VLST of DES.…”